
    
      The study is a randomized controlled trial. Patients who will use VKA are prospectively
      divided into routine group and pharmacist intervention group.

      For the intervention group, patients receive an intensive medical education from pharmacists
      in anticoagulation management service. Pharmacists regularly provide telephone and outpatient
      follow-up. At the end of the 12-month follow-up, the percentage of TTR and major bleeding
      events will be evaluated in both groups.

      Clinical data is designed to be collected from 800 patients, 400 patients in each group. Data
      will be analyzed by SPSS 20.0 software. P < 0.05 is considered significant.
    
  